Edwards Lifesciences expects 2026 profit to beat estimates on strong heart device demand
The medical device maker expects higher earnings due to robust demand for its artificial heart valves. Shares rose three percent following the announcement.
Insights:
Edwards Lifesciences Corporation announced on February 10, 2026, that it expects its adjusted profit for the 2026 fiscal year to exceed analysts' estimates, citing robust demand for artificial heart valves and other medical devices. The company's forward guidance, which was issued alongside strong fourth-quarter results, had an immediate market impact as shares rose in after-hours trading. This updated outlook reflects the company's confidence in its operational momentum and its ability to meet its stated financial objectives.
Supporting this improved 2026 outlook is the company's stated sales-growth target of 8% to 10%. Management cited several expected new-product catalysts as key drivers for future growth, specifically highlighting its transcatheter aortic valve replacement (TAVR) product. These catalysts are anticipated to bolster the company's position within the medical devices sector throughout 2026. The combination of strong quarterly performance and positive forward guidance has significantly influenced investor expectations at the company level.
